GlassScriptPhysician profile
April S Stowers
NPI 1003202805
$89,316.72
in general payments reported to CMS, 2019-2025
43 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $6,769 · 2023: $8,231 · 2024: $30K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $11K · Consulting Fee: $7,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,188.75 |
| Travel and Lodging | $21,159.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,957.50 |
| Food and Beverage | $11,087.87 |
| Consulting Fee | $7,627.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41,705.54 | 2022-2025 | Kisunla, Amyvid, Reyvow |
| Eisai INC. | $33,918.32 | 2021-2025 | |
| Eli Lilly and Company | $4,734.91 | 2024 | |
| Biogen, INC. | $1,151.18 | 2021-2025 | Vumerity, Tysabri, Aduhelm |
| Abbvie INC. | $994.63 | 2021-2025 | |
| Ucb, INC. | $853.16 | 2021-2025 | Briviact, Zilbrysq, Rystiggo |
| Ge Healthcare | $718.76 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $456.24 | 2023-2024 | Onpattro |
| Corium, LLC | $346.84 | 2023 | Adlarity |
| Amgen INC. | $325.33 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $325.32 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $312.80 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $303.79 | 2023-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $296.60 | 2021-2024 | Austedo Xr, Austedo |
| Emd Serono, INC. | $271.31 | 2022-2025 | Mavenclad |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Stowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.